Print

Featured Studies Results

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334/study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy


Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)

https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap

Clinicaltrials.gov identifier:
NCT05552755 (https://clinicaltrials.gov/show/NCT05552755)

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery


The American Cancer Society’s “VOICES of Black Women” Observational Study

https://www.facingourrisk.org/research-clinical-trials/study/336/the-american-cancer-societys-voices-of-black-women-observational-study

Surveys, Registries, Interviews
Survey for Black women who have never been diagnosed with cancer


Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation

Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor


Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

https://www.facingourrisk.org/research-clinical-trials/study/339/studying-the-effectiveness-of-new-parp-inhibitor-saruparib-compared-to-current-treatment-options-for-metastatic-prostate-cancer-evopar-pro1

Clinicaltrials.gov identifier:
NCT06120491 (https://clinicaltrials.gov/show/NCT06120491)

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer


Treating Metastatic Pancreatic Cancer Using a New Combination of Chemotherapy Drugs in People with a BRCA1, BRCA2 or PALB2 genetic or tumor mutation (The PLATINUM Trial)

https://www.facingourrisk.org/research-clinical-trials/study/338/treating-metastatic-brca1-brca2-or-palb2-pancreatic-cancer-using-a-new-combination-of-chemotherapy-drugs

Clinicaltrials.gov identifier:
NCT06115499 (https://clinicaltrials.gov/show/NCT06115499)

Treatment
Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation


Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/332/understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers


Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/335/understanding-the-emotional-and-social-experiences-of-individuals-living-with-ovarian-cancer

Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer


CHANCES: Studying the Connection Between Chemotherapy Exposure and Secondary Cancers of the Blood in Ovarian and other Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/325/chances-studying-the-connection-between-chemotherapy-exposure-and-secondary-cancers-of-the-blood-in-ovarian-cancer-survivors

Clinicaltrials.gov identifier:
NCT06295965 (https://clinicaltrials.gov/show/NCT06295965)

Prevention
Study focusing on improving outcomes for ovarian and other cancer survivors


Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 in Combination With Hormone Therapy (PETRANHA)

https://www.facingourrisk.org/research-clinical-trials/study/329/treating-metastatic-prostate-cancer-with-a-new-parp-inhibitor-azd5305-combined-with-hormone-therapy

Clinicaltrials.gov identifier:
NCT05367440 (https://clinicaltrials.gov/show/NCT05367440)

Treatment
Treatment study for metastatic prostate cancer


Cancer Risk Perception and Management of Individuals With a BRCA1 or BRCA2 Mutation Who Were Assigned Male at Birth (AMAB)

https://www.facingourrisk.org/research-clinical-trials/study/324/cancer-risk-perception-and-management-in-brca12-carriers-assigned-male-at-birth-amab

Surveys, Registries, Interviews
Research study enrolling individuals assigned male at birth (AMAB) who have a BRCA1 and/or BRCA2 mutation


Cognitive Training for Breast Cancer Survivors with Memory and Thinking Problems

https://www.facingourrisk.org/research-clinical-trials/study/312/cognitive-training-for-breast-cancer-survivors-with-memory-and-thinking-problems

Clinicaltrials.gov identifier:
NCT05896189 (https://clinicaltrials.gov/show/NCT05896189)

Quality of Life
How well cognitive training helps breast cancer survivors with their memory and thinking problems


PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease

Clinicaltrials.gov identifier:
NCT04472338 (https://clinicaltrials.gov/show/NCT04472338)

Prevention
Screening study for people with a mutation linked to prostate cancer risk


Social Support and Coping Strategies Among LGBTQIA+ Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/303/social-support-and-coping-strategies-among-lgbtqia-cancer-patients

Surveys, Registries, Interviews
Survey for LGBTQIA+ cancer patients who reside in the United States


Understanding the Cancer Journey: A Survey of Patient Experiences and Emotional Impact

https://www.facingourrisk.org/research-clinical-trials/study/319/understanding-the-cancer-journey-a-survey-of-patient-experiences-and-emotional-impact

Surveys, Registries, Interviews
Online survey for people diagnosed with breast, colorectal, gastric or prostate cancer within the past twenty years


The DETECT Study: Detecting Endometrial Cancer in Tampons

https://www.facingourrisk.org/research-clinical-trials/study/306/the-detect-study-detecting-endometrial-cancer-in-tampons

Clinicaltrials.gov identifier:
NCT03538665 (https://clinicaltrials.gov/show/NCT03538665)

Prevention
Early detection of endometrial cancer in women undergoing hysterectomy surgery at the University of Alabama


Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer

Clinicaltrials.gov identifier:
NCT05646316 (https://clinicaltrials.gov/show/NCT05646316)

Treatment
People with stage I endometrial cancer who are having a hysterectomy


The LiFT UP Li-Fraumeni & TP53: Understanding & Progress Study

https://www.facingourrisk.org/research-clinical-trials/study/307/the-lift-up-study

Clinicaltrials.gov identifier:
NCT04541654 (https://clinicaltrials.gov/show/NCT04541654)

Surveys, Registries, Interviews
Study looking at cancer risk for people with Li-Fraumeni syndrome


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.